ClinicalTrials.gg
CompletedNCT01591616Updated Aug 7, 2020Results posted

Pediatric Study to Access Pharmacokinetics and Safety of Oraqix Gel

A Phase 4 interventional study of lidocaine and prilocaine in Periodontal Disease, sponsored by Dentsply International. Completed at 1 site in United States. Open to participants aged 6 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-07.

Sponsored by Dentsply International · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 91 studies in Periodontal Diseases with a site in United States — 15 open to participants now, 17 under way, none of them phase 3. Periodontal Diseases · United States.

Enrollment
58th of 61
16 · median 60
Started
2010
with 6 others
Phase 4
6 of 91
1 open now
Registered
27th of 91
by date

Among the 91 studies in Periodontal Diseases with a site in United States, this one is the 58th largest by enrollment of the 61 interventional ones that give a count, is one of 7 that started in 2010, is one of 6 in phase 4, and was the 27th registered.

Periodontal Diseases

867 studies on the registry are indexed under Periodontal Diseases; 189 are open to participants now.

Browse Periodontal Diseases studies →

Open to participants now

15 of the 91 studies in Periodontal Diseases with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 101 Periodontal Diseases studies recruiting now, 47 (47%) set no upper age limit and 42 (42%) stop at 75 or younger; 5 take children under 18; 58 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in Periodontal Diseases with a site in United States, or all of them as a file.
02

Study summary

To establish Oraqix is safe when used on adolescent volunteers.

Read the detailed description

This is a single-center, uncontrolled, open-label, single administration patient study. Male and female subjects aged 6 through 17 years of age in need of primary tooth extraction will be recruited from the Principal Investigator's database and may be supplemented by advertising. Subjects who withdraw from the study prematurely will be replaced.

Subjects will undergo an initial screening visit at which eligibility will be determined. After completion of informed consent/assent a physical examination, vitals, 12-lead ECG, and dental examination will be conducted. A medical history will be documented and a blood sample will be collected for analysis of biochemistry, hematology and as appropriate, serum pregnancy assessment for females.

Subjects will return to the office approximately 1 to 10 days after Visit 1 for Visit 2. At Visit 2, study treatment will be administered and PK blood samples will be collected for analysis, and monitored for safety parameters. Up to a total of five cartridges of Oraqix® will be administered to the oral cavity in the area of the tooth extraction, based on the body weight of the subject. No more than five cartridges will be dispensed, since this is the maximum dose for this agent. The final sample will be collected 4 hours after administration of study material. An abbreviated dental examination will be conducted, any adverse events (AEs) will be documented and the subject will be discharged from the clinic.

All subjects will be contacted by telephone approximately 24 hours after administration of study treatment. Study personnel will enquire about the occurrence of any AEs that have occurred since leaving the office. If appropriate, further follow-up of AEs will be arranged. In the absence of any ongoing AEs requiring follow up the subject will be considered to have completed the study at the completion of the telephone call.

03

Conditions studied

  • Periodontal Disease

Browse trials for

04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 6 and 17 and eleven twelfths
  • requires tooth extraction
  • healthy having not taken any prescription or over the counter medications within 60 days of first visit
  • must be a minimum of 15 kg

Exclusion criteria

Exclusion Criteria:

  • anesthesia required for treatment other than study material
  • given blood within 90 days of first visit
  • pregnant
  • allergic to local anesthetic
  • documented history of glucose-6-phosphate dehydrogenase deficiency
  • history of congenital idiopathic methemoglobinemia
  • does not have a loose tooth easily extracted or who, in the opinion of the Investigator, is not suitable for tooth extraction using only topical anesthetic
05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Other
    Oraqix for tooth extraction

    Drug: lidocaine and prilocaine

Interventions

  • Druglidocaine and prilocaine

    Drug pages: Lidocaine · Prilocaine

    Appropriate dose of Oraqix based on weight will be given before tooth extraction

    Also known as: Oraqix periodontal gel

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics

    The study focused on the pharmacokinetics of prilocaine and lidocaine, o-toluidine (metabolite of prilocaine) and 2, 6-xylidine (metabolite of lidocaine). We evaluated blood samples of15 subjects at the following time points: pre-dose, at 5,10,15,30, 60, 90, 120 and 240 min post dose. We calculated Cmax (maximum observed plasma concentration) and Tmax (time to maximum plasma concentration).

    Time frame: 5, 10, 15, 30, 60, 90, 120, and 240 minutes

Secondary outcomes

  1. Safety

    The % MetHb levels and vital signs (pulse, systolic and diastolic pressure) were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose. ECG taken at pre-dose and 1, 2 and 4h post dose, measurement of heart rate and PR, QRS, QT and QTcB intervals. Visual analogue scale conducted at pre-dose (immediately before Oraqix administration), immed. post extraction, at 0.25, 0.5, 1 and 2h post dose and prior to discharge just after 4h post dose. For each subject, phone call was made at +24h as follow up pursuant to the protocol.

    Time frame: blood draws pre-dose, 2 and 4 hours postdose

  2. Vital Signs (Pulse)

    Vital signs (pulse, systolic and diastolic pressure) were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.

    Time frame: Pre-dose and every 10 minute to 240 minutes post-dose.

  3. Vital Signs (Systolic Pressure)

    Time frame: Pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.

  4. Vital Signs (Diastolic Pressure)

    Time frame: Pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose

  5. ECGs (Ventricular Heart Rate)

    Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.

    Time frame: Pre-dose, 1 hour, 2 hour, 4 hour post-dose.

  6. ECGs (PR Interval)

    Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.

    Time frame: Pre-dose, 1 hour, 2 hour, 4 hour post-dose.

  7. ECGs (QRS Duration)

    Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.

    Time frame: Pre-dose, 1 hour, 2 hour, 4 hour post-dose.

  8. ECGs (QT Interval)

    Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.

    Time frame: Pre-dose, 1 hour, 2 hour, 4 hour post-dose.

  9. ECGs (QTcB Interval)

    Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.

    Time frame: Pre-dose, 1 hour, 2 hour, 4 hour post-dose.

07

Results

Posted Apr 3, 2014

Participant flow

Participant flow — Overall Study
MilestoneOraqix for Tooth Extraction
Started16
Completed15
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryPharmacokinetics

The study focused on the pharmacokinetics of prilocaine and lidocaine, o-toluidine (metabolite of prilocaine) and 2, 6-xylidine (metabolite of lidocaine). We evaluated blood samples of15 subjects at the following time points: pre-dose, at 5,10,15,30, 60, 90, 120 and 240 min post dose. We calculated Cmax (maximum observed plasma concentration) and Tmax (time to maximum plasma concentration).

Time frame:
5, 10, 15, 30, 60, 90, 120, and 240 minutes
Reported as:
Geometric mean · ng/mL
Pharmacokinetics
ng/mLLidocaine CmaxPrilocaine Cmax2,6-xylidine CmaxO-toluidine Cmax
Pharmacokinetics89.9 ± 6641.8 ± 60.63.72 ± 48.55.13 ± 51.2
SecondarySafety

The % MetHb levels and vital signs (pulse, systolic and diastolic pressure) were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose. ECG taken at pre-dose and 1, 2 and 4h post dose, measurement of heart rate and PR, QRS, QT and QTcB intervals. Visual analogue scale conducted at pre-dose (immediately before Oraqix administration), immed. post extraction, at 0.25, 0.5, 1 and 2h post dose and prior to discharge just after 4h post dose. For each subject, phone call was made at +24h as follow up pursuant to the protocol.

Time frame:
blood draws pre-dose, 2 and 4 hours postdose
Reported as:
Mean · Percentage MetHb
Safety
Percentage MetHb% MetHemoglobin (MetHb) Time Point -20 Minutes% MetHemoglobin (MetHb) Time Point -10 Minutes% MetHemoglobin (MetHb) Time Point 0 Minutes% MetHemoglobin (MetHb) Time Point 10 Minutes% MetHemoglobin (MetHb) Time Point 20 Minutes% MetHemoglobin (MetHb) Time Point 30 Minutes% MetHemoglobin (MetHb) Time Point 40 Minutes% MetHemoglobin (MetHb) Time Point 50 Minutes% MetHemoglobin (MetHb) Time Point 60 Minutes% MetHemoglobin (MetHb) Time Point 70 Minutes% MetHemoglobin (MetHb) Time Point 80 Minutes% MetHemoglobin (MetHb) Time Point 90 Minutes% MetHemoglobin (MetHb) Time Point 100 Minutes% MetHemoglobin (MetHb) Time Point 110 Minutes% MetHemoglobin (MetHb) Time Point 120 Minutes% MetHemoglobin (MetHb) Time Point 130 Minutes% MetHemoglobin (MetHb) Time Point 140 Minutes% MetHemoglobin (MetHb) Time Point 150 Minutes% MetHemoglobin (MetHb) Time Point 160 Minutes% MetHemoglobin (MetHb) Time Point 170 Minutes% MetHemoglobin (MetHb) Time Point 180 Minutes% MetHemoglobin (MetHb) Time Point 190 Minutes% MetHemoglobin (MetHb) Time Point 200 Minutes% MetHemoglobin (MetHb) Time Point 210 Minutes% MetHemoglobin (MetHb) Time Point 220 Minutes% MetHemoglobin (MetHb) Time Point 230 Minutes% MetHemoglobin (MetHb) Time Point 240 Minutes
Safety1.3 ± 0.241.3 ± 0.261.2 ± 0.201.2 ± 0.201.3 ± 0.181.5 ± 0.431.5 ± 0.201.6 ± 0.191.7 ± 0.281.7 ± 0.301.5 ± 0.351.5 ± 0.401.5 ± 0.391.6 ± 0.191.5 ± 0.321.5 ± 0.291.4 ± 0.281.4 ± 0.261.3 ± 0.341.2 ± 0.471.4 ± 0.151.4 ± 0.171.5 ± 0.201.4 ± 0.181.4 ± 0.131.5 ± 0.141.4 ± 0.15
PrimaryPharmacokinetics

The study focused on the pharmacokinetics of prilocaine and lidocaine, o-toluidine (metabolite of prilocaine) and 2, 6-xylidine (metabolite of lidocaine). We evaluated blood samples of15 subjects at the following time points: pre-dose, at 5,10,15,30, 60, 90, 120 and 240 min post dose. We calculated Cmax (maximum observed plasma concentration) and Tmax (time to maximum plasma concentration).

Time frame:
5, 10, 15, 30, 60, 90, 120, and 240 minutes
Reported as:
Geometric mean · hours
Pharmacokinetics
hoursLidocaine TmaxPrilocaine Tmax2,6-xylidine TmaxO-toluidine Tmax
Pharmacokinetics0.500 (0.0833 to 0.650)0.500 (0.0833 to 0.650)1.50 (0.650 to 4.00)1.50 (1.00 to 1.50)
SecondaryVital Signs (Pulse)

Vital signs (pulse, systolic and diastolic pressure) were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.

Time frame:
Pre-dose and every 10 minute to 240 minutes post-dose.
Reported as:
Mean · Beats per minute
Vital Signs (Pulse)
Beats per minuteVital Signs (Pulse Rate), - 20 Minutes Pre-doseVital Signs (Pulse Rate), - 10 Minutes Pre-doseVital Signs (Pulse Rate), 0 Minutes Pre-doseVital Signs (Pulse Rate), 10 Minutes Post-doseVital Signs (Pulse Rate), 20 Minutes Post-doseVital Signs (Pulse Rate), 30 Minutes Post-doseVital Signs (Pulse Rate), 40 Minutes Post-doseVital Signs (Pulse Rate), 50 Minutes Post-doseVital Signs (Pulse Rate), 60 Minutes Post-doseVital Signs (Pulse Rate), 70 Minutes Post-doseVital Signs (Pulse Rate), 80 Minutes Post-doseVital Signs (Pulse Rate), 90 Minutes Post-doseVital Signs (Pulse Rate), 100 Minutes Post-doseVital Signs (Pulse Rate), 110 Minutes Post-doseVital Signs (Pulse Rate), 120 Minutes Post-doseVital Signs (Pulse Rate), 130 Minutes Post-doseVital Signs (Pulse Rate), 140 Minutes Post-doseVital Signs (Pulse Rate), 150 Minutes Post-doseVital Signs (Pulse Rate), 160 Minutes Post-doseVital Signs (Pulse Rate), 170 Minutes Post-doseVital Signs (Pulse Rate), 180 Minutes Post-doseVital Signs (Pulse Rate), 190 Minutes Post-doseVital Signs (Pulse Rate), 200 Minutes Post-doseVital Signs (Pulse Rate), 210 Minutes Post-doseVital Signs (Pulse Rate), 220 Minutes Post-doseVital Signs (Pulse Rate), 230 Minutes Post-doseVital Signs (Pulse Rate), 240 Minutes Post-dose
Vital Signs (Pulse)74 (58 to 98)72 (54 to 90)72 (60 to 95)79 (59 to 101)71 (58 to 89)72 (56 to 94)71 (55 to 86)70 (54 to 86)71 (55 to 86)74 (61 to 89)72 (57 to 86)71 (53 to 90)70 (54 to 91)72 (57 to 88)70 (52 to 86)71 (58 to 91)72 (53 to 97)72 (55 to 98)74 (58 to 93)74 (57 to 100)73 (53 to 91)72 (50 to 90)75 (62 to 90)72 (54 to 97)70 (53 to 96)72 (57 to 96)77 (62 to 101)
SecondaryVital Signs (Systolic Pressure)
Time frame:
Pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.
Reported as:
Mean · mmHg
Vital Signs (Systolic Pressure)
mmHgVital Signs (Systolic), - 20 Minutes Pre-doseVital Signs (Systolic), - 10 Minutes Pre-doseVital Signs (Systolic), 0 Minutes Pre-doseVital Signs (Systolic), 10 Minutes Post-doseVital Signs (Systolic), 20 Minutes Post-doseVital Signs (Systolic), 30 Minutes Post-doseVital Signs (Systolic), 40 Minutes Post-doseVital Signs (Systolic), 50 Minutes Post-doseVital Signs (Systolic), 60 Minutes Post-doseVital Signs (Systolic), 70 Minutes Post-doseVital Signs (Systolic) 80 Minutes Post-doseVital Signs (Systolic), 90 Minutes Post-doseVital Signs (Systolic), 100 Minutes Post-doseVital Signs (Systolic), 110 Minutes Post-doseVital Signs (Systolic), 120 Minutes Post-doseVital Signs (Systolic), 130 Minutes Post-doseVital Signs (Systolic), 140 Minutes Post-doseVital Signs (Systolic), 150 Minutes Post-doseVital Signs (Systolic), 160 Minutes Post-doseVital Signs (Systolic), 170 Minutes Post-doseVital Signs (Systolic), 180 Minutes Post-doseVital Signs (Systolic), 190 Minutes Post-doseVital Signs (Systolic), 200 Minutes Post-doseVital Signs (Systolic), 210 Minutes Post-doseVital Signs (Systolic), 220 Minutes Post-doseVital Signs (Systolic), 230 Minutes Post-doseVital Signs (Systolic), 240 Minutes Post-dose
Vital Signs (Systolic Pressure)110 ± 11.5104 ± 9.4106 ± 9.1115 ± 9.7109 ± 7.9108 ± 9.4106 ± 9.8106 ± 9.6105 ± 12.1106 ± 7.9104 ± 11.0106 ± 9.7106 ± 9.9106 ± 10.7106 ± 11.4105 ± 8.9108 ± 8.0107 ± 8.4105 ± 10.7106 ± 9.6104 ± 10.2103 ± 10.7103 ± 10.9102 ± 9.2104 ± 10.8102 ± 10.6102 ± 11.7
SecondaryVital Signs (Diastolic Pressure)
Time frame:
Pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose
Reported as:
Mean · mmHg
Vital Signs (Diastolic Pressure)
mmHgVital Signs (Diastolic), - 20 Minutes Pre-doseVital Signs (Diastolic), - 10 Minutes Pre-doseVital Signs (Diastolic), 0 Minutes Pre-doseVital Signs (Diastolic), 10 Minutes Post-doseVital Signs (Diastolic), 20 Minutes Post-doseVital Signs (Diastolic), 30 Minutes Post-doseVital Signs (Diastolic), 40 Minutes Post-doseVital Signs (Diastolic), 50 Minutes Post-doseVital Signs Diastolic(), 60 Minutes Post-doseVital Signs (Diastolic), 70 Minutes Post-doseVital Signs (Diastolic) 80 Minutes Post-doseVital Signs (Diastolic), 90 Minutes Post-doseVital Signs (Diastolic), 100 Minutes Post-doseVital Signs (Diastolic), 110 Minutes Post-doseVital Signs (Diastolic), 120 Minutes Post-doseVital Signs Diastolic(), 130 Minutes Post-doseVital Signs (Diastolic), 140 Minutes Post-doseVital Signs (Diastolic), 150 Minutes Post-doseVital Signs (Diastolic), 160 Minutes Post-doseVital Signs (Diastolic), 170 Minutes Post-doseVital Signs (Diastolic), 180 Minutes Post-doseVital Signs (Diastolic), 190 Minutes Post-doseVital Signs (Diastolic), 200 Minutes Post-doseVital Signs (Diastolic), 210 Minutes Post-doseVital Signs (Diastolic), 220 Minutes Post-doseVital Signs (Diastolic), 230 Minutes Post-doseVital Signs (Diastolic), 240 Minutes Post-dose
Vital Signs (Diastolic Pressure)63 ± 6.860 ± 7.263 ± 7.269 ± 7.963 ± 6.264 ± 5.662 ± 8.762 ± 11.262 ± 7.762 ± 10.862 ± 9.364 ± 7.663 ± 7.663 ± 11.460 ± 7.662 ± 7.962 ± 7.263 ± 9.163 ± 6.660 ± 6.860 ± 8.861 ± 7.160 ± 7.659 ± 7.557 ± 6.957 ± 6.960 ± 8.4
SecondaryECGs (Ventricular Heart Rate)

Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.

Time frame:
Pre-dose, 1 hour, 2 hour, 4 hour post-dose.
Reported as:
Mean · Beats per minute
ECGs (Ventricular Heart Rate)
Beats per minuteVentricular Heart Rate, Pre-doseVentricular Heart Rate, 1 Hour Post-doseVentricular Heart Rate, 2 Hour Post-doseVentricular Heart Rate, 4 Hour Post-dose
ECGs (Ventricular Heart Rate)73 ± 9.970 ± 8.371 ± 6.574 ± 10.1
SecondaryECGs (PR Interval)

Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.

Time frame:
Pre-dose, 1 hour, 2 hour, 4 hour post-dose.
Reported as:
Mean · milliseconds
ECGs (PR Interval)
millisecondsPR Interval, Pre-dosePR Interval, 1 Hour Post-dosePR Interval, 2 Hour Post-dosePR Interval, 4 Hour Post-dose
ECGs (PR Interval)148 ± 21.1147 ± 23.7147 ± 22.4139 ± 18.9
SecondaryECGs (QRS Duration)

Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.

Time frame:
Pre-dose, 1 hour, 2 hour, 4 hour post-dose.
Reported as:
Mean · milliseconds
ECGs (QRS Duration)
millisecondsQRS Duration, Pre-doseQRS Duration, 1 Hour Post-doseQRS Duration, 2 Hour Post-doseQRS Duration, 4 Hour Post-dose
ECGs (QRS Duration)77 ± 5.776 ± 4.575 ± 7.574 ± 5.3
SecondaryECGs (QT Interval)

Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.

Time frame:
Pre-dose, 1 hour, 2 hour, 4 hour post-dose.
Reported as:
Mean · milliseconds
ECGs (QT Interval)
millisecondsQT Interval, Pre-doseQT Interval, 1 Hour Post-doseQT Interval, 2 Hour Post-doseQT Interval, 4 Hour Post-dose
ECGs (QT Interval)376 ± 22.5384 ± 19.3383 ± 19.0379 ± 25.8
SecondaryECGs (QTcB Interval)

Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.

Time frame:
Pre-dose, 1 hour, 2 hour, 4 hour post-dose.
Reported as:
Mean · milliseconds
ECGs (QTcB Interval)
millisecondsQTcB Interval, Pre-doseQTcB Interval, 1 Hour Post-doseQTcB Interval, 2 Hour Post-doseQTcB Interval, 4 Hour Post-dose
ECGs (QTcB Interval)412 ± 19.0413 ± 21.9415 ± 18.6419 ± 21.1

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adverse Events—0/16 (0%)2/16 (12.5%)
Most frequent other events
Most frequent other events
EventAdverse Events
NauseaGastrointestinal disorders2/16
GaggingGastrointestinal disorders1/16
VomitingGastrointestinal disorders1/16
Tooth painNervous system disorders1/16
HeadacheNervous system disorders1/16

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Oraqix for Tooth Extraction
<=18 years16
Between 18 and 65 years0
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Oraqix for Tooth Extraction
Female9
Male7
Region of Enrollment
Region of Enrollment(participants)Oraqix for Tooth Extraction
United States16
08

Study locations

1 site
  • Virginia Commonweath School of Dentistry
    Richmond, Virginia 23298, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2010, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2011
First posted
May 4, 2012
Start
Apr 2010
Primary completionActual
Apr 2012
CompletionActual
Apr 2012
Results first posted
Apr 3, 2014
Last update
Aug 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01591616
Responsible party
Sponsor
First posted
May 4, 2012
Start date
Apr 2010
Primary completion
Apr 2012
Completion
Apr 2012
Results posted
Apr 3, 2014
Last update
Aug 7, 2020

Study contacts

Tegwyn Brickhouse, D.D.S PhD
principal investigator · Virginia Commonweath School of Dentistry

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lidocaine · Prilocaine

Start the discussion